RSC Medicinal Chemistry

RSC Medicinal Chemistry 由 ROYAL SOC CHEMISTRY 出版，属中科院医学大类（2025 升级版3区）。按 OpenAlex 近年发文统计，该刊主要发表 Synthesis and biological activity、Click Chemistry and Applications、Computational Drug Discovery Methods 等主题的论文，这 3 个主题约占 29.6%，主导子领域为 Organic Chemistry、Molecular Biology。（根据 OpenAlex 主题统计与中科院分区数据生成）

Research articles published in this journal must show a breakthrough or significant advance on previously published work, or bring new thinking or results that will have a strong impact in their field. Examples of areas within the journal's scope are: Design, synthesis and biological evaluation of novel chemical entities or biotherapeutic modalities. To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs.Modifications of known chemical entities or biotherapeutic modalities that result in a significantly greater understanding of their structure-activity relationships, an improvement of their properties or provide other information of significant value, for example, the identification of a new target or mode of action for a known agent. Routine modifications with minimal or no improvement are not suitable for RSC Medicinal Chemistry.Novel methodologies and technologies in the broader chemical and biological sciences (for example, enabling synthetic chemistry, chemical biology, -omics sciences, nanoscience) with application to drug discovery, target identification or elucidation of the mechanism of action. Biological studies should present sufficient innovation with respect to the chemistry.Computational studies are welcome where they significantly advance medicinal chemistry knowledge. Studies that use established computational methods should include an original prediction and be accompanied by new experimental data which validates the prediction made. Studies that report novel computational methodology must demonstrate its use in medicinal chemistry through comparison with experimental data. Computational research that does not clearly relate the results obtained to experimental data or that has no demonstrated utility (or where the utility is unlikely to advance the field significantly) is not suitable for RSC Medicinal Chemistry. Docking studies presented without experimental data are not suitable for publication in the journal.Studies that examine the effect of the molecular structure of a compound on pharmacokinetic behaviour and pharmacodynamics.Studies that present new insights into drug design based on analysis of existing experimental datasets or new theoretical approaches if supported by experimental evidence.Studies presenting new drug delivery systems with novel chemical agents are welcomed, in particular those that involve chemical modification of the delivery syste

摘自期刊官网 Aims & Scope

研究方向（LetPub）：Multiple

主编 Mike Waring出版商官网

编委会国家分布：中国大陆 1 位（约 25%）；主要国家 中国 1、印度 1、西班牙 1、澳大利亚 1（共 4 位编委标注了国家） 编委会 ↗出版商官网 · 2026-10-01

中科院期刊分区表

数据库收录

SCIEScopusLetPub

国际期刊预警名单：各版本均未列入LetPub

期刊官网自述收录

Web of SciencePubMed出版商官网

期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子

4.64LetPub · 2026-09-13

影响因子（出版商公布） 2025

4.6出版商官网 · 2026-10-01

CiteScore 2026-06

5.7LetPub · 2026-09-13

SJR 2026-06

0.76LetPub · 2026-09-13

SNIP 2026-06

0.98LetPub · 2026-09-13

h-index

53OpenAlex · 2026-10-01

i10-index

511OpenAlex · 2026-10-01

两年平均被引

4.58OpenAlex · 2026-10-01

自引率

2.2%LetPub · 2026-09-13

Gold OA 文章占比

28.86%LetPub · 2026-09-13

发文规模

年文章数

369LetPub · 2026-09-13

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

其他来源

投稿到首次决定

11 天出版商官网 · 2026-10-01

评审方式

单盲同行评审、开放同行评审出版商官网

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

ROYAL SOC CHEMISTRY

出版国家或地区

ENGLAND

ISSN

2632-8682

官方链接

• 期刊主页 ↗OpenAlex
• 投稿系统 ↗出版商官网
• 专刊 / 特刊征稿 ↗出版商官网